Glenmark Pharmaceuticals Inc., USA, announced the upcoming launch of its generic version of Adderall®—a combination drug containing Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate. The medication, classified as Mixed Salts of a Single Entity Amphetamine Product, will be available in 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strengths.
The product has been approved as bioequivalent and therapeutically equivalent to the reference listed drug, Adderall® Tablets, marketed by Teva Women’s Health, Inc. Glenmark plans to begin distribution in May 2025.
Adderall® is widely prescribed in the United States for the treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy. According to IQVIA™ sales data for the 12-month period ending February 2025, Adderall® Tablets across all strengths generated approximately $421.7 million in annual sales.
Marc Kikuchi, President and Business Head, North America at Glenmark, highlighted that the launch addresses ongoing supply challenges in the market. The introduction of this generic alternative aims to improve accessibility for patients who rely on these medications.
Glenmark’s new product will be available by prescription through standard pharmaceutical distribution channels starting May 2025.
